🇺🇸 FDA
Pipeline program

FCD105

FX2016-40

Phase 2 other completed

Quick answer

FCD105 for Acne Vulgaris is a Phase 2 program (other) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
VYNE Therapeutics
Indication
Acne Vulgaris
Phase
Phase 2
Modality
other
Status
completed

Clinical trials